EQT acquires molecular diagnostics specialist in €10.80bn takeover
Swedish private equity group EQT is acquiring listed German-Dutch diagnostics specialist Qiagen in a transaction that values the target at an enterprise value of approximately €10.80bn. The transaction represents a major consolidation in the European life sciences and molecular diagnostics landscape. Qiagen operates extensively across sample preparation, molecular diagnostics, and life sciences research fields, with its technologies widely deployed in…
EQT targets surgical technology with Corza Biosurgery deal
Global investment firm EQT is to acquire the biosurgery business unit from Chicago-based private equity firm GTCR’s portfolio company, Corza Medical. Financial details of the transaction remain undisclosed. The deal, through the EQT X fund, is expected to close in Q4 2026, subject to regulatory clearances and customary closing conditions. The divestiture represents a significant corporate carve-out for Corza Medical. Under…
EQT and co-investors fully exit Galderma
Swedish private equity firm EQT has fully divested from Swiss-based global pure-play dermatology company Galderma. On March 13, EQT and its co-investors, including the Abu Dhabi Investment Authority and Singapore’s GIC, offloaded their remaining 14.3% stake. The sale of approximately 34 million shares generated roughly 4.9 billion Swiss francs (£4.65bn), making it the largest sponsor-backed block trade in history. The…